Sector: Chemicals

Latest content

PepsiCo suffers big loss following David-vs-Goliath battle with Indian farmers

India revokes company’s exclusive right to potato variety used in Lay’s chips, in case that illustrates limits of country’s agricultural IP protections

10 December 2021

Germany’s new government is the last hope for covid IP waiver advocates

A post-Merkel change of approach by the country’s recently agreed traffic light coalition government could change the momentum of TRIPS suspension talks – but don’t bet on it

07 December 2021

USPTO rejections: post-Alice insights

Featured in Special Report 2021 Q4: IP5 insights

29 November 2021

Why CNIPA could be the go-to venue for Chinese patent linkage plaintiffs

Pharma patentees face difficult choices under the country’s new early dispute resolution framework

19 November 2021

Generics are the winners as CAFC doubles down on strict Hatch-Waxman venue selection criteria

A decision handed down last Friday against Celgene elaborates on the rules set out in the landmark Valeant case and makes life tough for pharma patent owners

09 November 2021

European plausibility uncertainties could be cleared up by new Enlarged Board of Appeal referral

The EPO is seeking clarity on a crucial question facing patentees, but not everyone is sure that a recent referral is the best vehicle

04 November 2021

China to let foreign patent agencies set up representative offices

Prosecution firms will be able to advise local clients on overseas filings and IP risks, but Chinese patent practice will remain out-of-bounds

28 October 2021

Oppo, Huawei were most prolific patent challengers in China last year

Exclusive invalidation statistics from IncoPat show the busiest companies on the offensive and the defensive at the CNIPA

25 October 2021

How a new business strategy at GlobalFoundries has affected its push for patents

The semiconductor company is taking a narrower approach to both R&D and IP procurement as it focuses on the foundry market

14 October 2021

CAFC decision highlights continued danger of inequitable conduct rulings

The Federal Circuit’s judgment in a recent pharma patent case is a stark reminder that IP professionals must remain vigilant

16 September 2021

Unlock unlimited access to all IAM content